CenterBook Partners LP Has $10.04 Million Stock Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

CenterBook Partners LP raised its stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 98.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 305,599 shares of the biopharmaceutical company's stock after acquiring an additional 151,511 shares during the quarter. CenterBook Partners LP owned approximately 0.54% of Agios Pharmaceuticals worth $10,042,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Venturi Wealth Management LLC acquired a new position in shares of Agios Pharmaceuticals in the 4th quarter worth approximately $33,000. Wingate Wealth Advisors Inc. acquired a new position in Agios Pharmaceuticals in the fourth quarter worth $53,000. KBC Group NV grew its holdings in shares of Agios Pharmaceuticals by 30.5% during the fourth quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company's stock worth $86,000 after purchasing an additional 611 shares during the last quarter. AlphaQuest LLC increased its stake in shares of Agios Pharmaceuticals by 106.2% in the fourth quarter. AlphaQuest LLC now owns 4,540 shares of the biopharmaceutical company's stock valued at $149,000 after buying an additional 2,338 shares in the last quarter. Finally, AlphaCentric Advisors LLC bought a new position in shares of Agios Pharmaceuticals in the fourth quarter valued at about $202,000.

Insider Transactions at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, Director Jacqualyn A. Fouse sold 7,497 shares of the firm's stock in a transaction that occurred on Thursday, April 10th. The shares were sold at an average price of $25.90, for a total transaction of $194,172.30. Following the sale, the director now directly owns 149,220 shares in the company, valued at approximately $3,864,798. This trade represents a 4.78 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 4.93% of the company's stock.

Remove Ads

Agios Pharmaceuticals Stock Performance

AGIO traded up $0.44 during midday trading on Monday, reaching $27.14. 211,656 shares of the company were exchanged, compared to its average volume of 708,945. The stock has a market capitalization of $1.56 billion, a P/E ratio of 2.39 and a beta of 0.83. Agios Pharmaceuticals, Inc. has a one year low of $23.42 and a one year high of $62.58. The stock's 50-day simple moving average is $31.39 and its 200 day simple moving average is $39.18.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. On average, research analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on AGIO shares. Cantor Fitzgerald reissued an "overweight" rating on shares of Agios Pharmaceuticals in a report on Wednesday, December 18th. HC Wainwright initiated coverage on shares of Agios Pharmaceuticals in a research note on Monday, February 24th. They set a "buy" rating and a $58.00 price target on the stock. Finally, StockNews.com downgraded Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Friday, February 14th. One research analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, Agios Pharmaceuticals presently has an average rating of "Hold" and an average price target of $56.57.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.